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Background: To determine clinical-pathologic variables in patients with a new diagnosis of hepatocellular
carcinoma (HCC) and underlying hepatitis B vs. C infection.
Methods: Patients presenting to a single urban hospital with a new diagnosis of HCC were entered into a clinical
database. Variables including number and size of tumors, presence of metastases, serum alpha-Fetoprotein,
hepatitis serologies, severity of hepatic dysfunction, and presence of cirrhosis were evaluated in 127 patients.
Results: Patients with hepatitis B (HBV) were more likely to develop HCC at a younger age than patients with
hepatitis C (HCV) (HBV-26% under age 40, HCV-0% under age 40; p< 0.001), with greater serum alpha-Fetoprotein
production (median level: HBV-1000 ng/ml vs. HCV-37 ng/ml; p = 0.002), with larger tumors (HBV-78% >5 cm, HCV-28
% >5 cm; p< 0.001), in the absence of cirrhosis (HBV-40%, HCV-0%; p< 0.001), and a decreased eligibility for curative
treatment (HBV-14%, HCV-34%; p< 0.05). Conversely, patients with HCV were more likely to develop HCC in
association with multiple co-morbidities, cirrhosis, and older age.
Conclusions: Significant clinical-pathologic differences exist among HCC patients with underlying HBV vs. HCV.
These differences impact eligibility for potentially-curative therapy and prognosis.
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Hepatocellular Carcinoma (HCC) is the third leading
cause of cancer related mortality worldwide [1]. The glo-
bal prevalence and mortality resulting from HCC is dir-
ectly related to underlying risk factors for primary liver
cancer in at-risk populations. Although several chronic
liver diseases are associated with HCC, Hepatitis B Virus
(HBV) and Hepatitis C Virus (HCV) statistically are the
most commonly implicated risk factors. Combined they
are responsible for 85% of total new HCC cases world-
wide; 54% occurring as a result of HBV, and 31% as a re-
sult of HCV [2,3]. HBV, which is endemic in developing
geographic regions such as Eastern Asia and Sub-
Saharan Africa, is responsible for up to 90% of new
HCC cases in such areas [4].
Epidemiologic analyses and clinical series which lead to
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reproduction in any medium, provided the orHCC do not usually subset results according the under-
lying viral risk factors for the disease [5]. Most survival
analyses from institutions with broad experience in surgi-
cal resection, transplantation, ablation, transarterial che-
moembolization, or other treatments usually combine
patients, irrespective of their underlying viral hepatitis
status or association to other risk factors [6,7]. Therefore
variations in patterns of presentation, tumor biology, or
treatment outcomes for HCC according to underlying as-
sociation to viral hepatitis B or C remain unclear.
Despite histologic similarities in end-organ damage
and eventual carcinomas, adequate scientific rationale
supports a proposed hypothesis that distinct pathophy-
siologic mechanisms may be responsible for hepatocarci-
nogenesis due to either HBV or HCV. This is based in
part on marked virologic differences seen among the 2
pathogens. Hepatitis B is a DNA virus belonging to the
Hepadna virus family, which persists in the hepatocyte
nucleus predominantly in the form of covalently closed
circular DNA (cccDNA), the functional template for
viral transcription and replication [8]. Conversely, Hepa-
titis C is an RNA virus belonging to the flavivirus familytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Hiotis et al. BMC Gastroenterology 2012, 12:64 Page 2 of 7
http://www.biomedcentral.com/1471-230X/12/64which replicates in the hepatocyte cytoplasm, with a
completely distinct life cycle and pattern of viral replica-
tion [9,10]. Differences in natural history of resulting be-
nign liver disease is well-described among the 2 viruses
[11].
In this study, an attempt has been made to evaluate
potentially significant clinical-pathologic differences in
HCC’s that develop in association with chronic HBV vs.
HCV. Comparisons have been made among two other-
wise comparable groups according to data collected
upon initial cancer diagnosis at a single, urban hospital.
Demographic data and widely accepted relevant clinical-
pathologic features of newly diagnosed HCC’s have been
collected with the intended purpose of delineating po-
tentially significant differences in cancers which arise in
HBV vs. HCV infected patients.
Methods
Database enrollment
Patients were enrolled into a clinical database based
upon a diagnosis of HCC at a single New York City pub-
lic hospital (Bellevue Hospital Center). The database was
approved by the IRB of New York University Medical
Center and was in compliance with the Helsinki Declar-
ation. The overall period of enrolment spanned the years
of 1993 to 2005. Data for patients diagnosed between
1993 and 2001 was collected in a retrospective manner,
while data collected between the years of 2001 and 2005
was entered prospectively. This study was exempt from
IRB approval according to the institutional criteria at
New York University Medical Center. Hence, informed
consent was not required for this study.
Demographic data including age, sex, race, and ethni-
city were collected. Several clinical-pathologic features
were also recorded upon initial HCC diagnosis including
the following: tumor size, tumor number, presence of
synchronous distant metastases, macro-vascular invasion
(tumor thrombus), viral hepatitis serologies, serum bio-
chemistries including liver function tests, serum alpha-
fetoprotein, presence and severity (according to Childs-
Pugh classification) of coexisting cirrhosis, and under-
lying co morbidities.
In subsequent retrospective analysis of database vari-
ables, patients were stratified according to underlying
risk factors for HCC. In order to facilitate a cohort com-
parison of HBV vs. HCV as risk factors for cancer,
patients with either HBV or HCV only were included for
analysis. Those co-infected both with HBV and HCV, or
neither hepatitis virus were excluded from this analysis.
Diagnosis of HCC
The diagnosis of HCC was based upon histology or cy-
tology, when tissue was available following surgical re-
section or biopsy. For cases in which no tissue wasavailable, patients were diagnosed with HCC if dynamic
imaging findings (CT with intravenous contrast or MRI
only) of a hypervascular solid liver mass with features
characteristic for HCC were present in a setting of
underlying risk factors, along with a clearly elevated
serum alpha-fetoprotein (>100 ng/ml). A diagnosis of
HCC for all patients that presented with non-AFP-
producing tumors was confirmed by biopsy. Of all 127
patients, 76 (60%) were diagnosed based upon histology
or cytology, while 51 (40%) were diagnosed with imaging
along with other features.
Diagnosis of cirrhosis
A diagnosis of cirrhosis was made based on a combin-
ation of clinical parameters. For patients in whom tissue
(from biopsy of resection specimens) was available from
the non-neoplastic liver, a diagnosis of cirrhosis was
made if histologic findings of hepatic fibrosis were
observed in conjunction with clinical evidence of severe
hepatic dysfunction (such as hypoalbuminemia). Patients
with available histologic specimens demonstrating no
evidence of hepatic fibrosis were deemed non-cirrhotic.
For patients in whom non-neoplastic liver tissue was un-
available, a diagnosis of cirrhosis was based upon a com-
bination of axial imaging features (including hepatic
macronodularity and ascites), serum biochemistries indi-
cative of severe hepatic dysfunction (such as hypoalbu-
minemia), and physical exam findings such as documented
ascites.
Statistical analyses
Comparisons of patient cohorts were performed using
Fisher’s exact test. A p value of <0.05 was used to desig-
nate a statistically significant difference among observed
vs. expected outcomes.
Results
Demographics, age distribution, and underlying
comorbidities
A total of 149 HCC patients were enrolled during the
study period: 89 (59.7%) with HBV-associated cancers,
38 (25.5%) with HCV-associated cancers, 4 (2.7%) with
cancers associated with both HBV and HCV, and 18
patients (12.1%) with cancers not associated with either
hepatitis virus (Figure 1). HCC patients with HBV and
HCV co-infection, as well as those without underlying
viral hepatitis were excluded from the present analysis.
HCC developed more commonly among males in both
groups, however the association to male gender was
stronger in the HBV group. Only 5% of HBV-associated
HCC’s developed in female patients compared with 21%
of HCV-associated HCC’s (p = 0.007, Table 1). The ma-
jority of HBV-associated HCC patients were of Asian
Figure 1 HCC incidence according to underlying etiology
(current series). Underlying risk factors for HCC in current series
closely resembles global demographic: worldwide epidemiologic
data estimate HCC due to HBV in 53-54% of total cases, and due to
HCV in 25%-31% of cases.
Table 1 Demographic and clinical-pathologic
comparisons of patients with HCC associated with









Male 115 (90%) 85 (95%) 30 (79%) p = 0.007
Female 12 (10%) 4 (5%) 8 (21%)
Race
Asian 82 (65%) 80 (90%) 2 (5%) p< 0.001
Non-Asian 45 (35%) 9 (10%) 36 (95%)
Age
Median 53 50 58 NS
Range 21-79 21-75 47-79
Distribution
21-30 5 (4%) 5 (6%) 0 (0%)
31-40 18 (14%) 18 (20%) 0 (0%) p< 0.001 {
41-50 23 (18%) 21 (24%) 2 (5%)
51-60 50 (39%) 28 (31%) 22 (58%)
>60 31 (24%) 17 (19%) 14 (37%)
Comorbidities
Mean± S.D 1.6 ± 1.6 1.0 ± 1.1 2.9 ± 1.5 p< 0.001
Alcohol abuse
18 (15%) 6 (7%) 12 (32%) p< 0.001
HIV coinfection
8 (6%) 1 (1%) 7 (13%) p< 0.001
Cirrhosis state in the non-neoplastic liver (n = 119)
Non-cirrhosis 34 (29%) 34 (40%) 0 (0%) p< 0.001
Cirrhosis 85 (71%) 50 (60%) 35 (100%)
AFP levels (n = 122)
Median 137 1000 37 p = 0.002
Range 3-871,485 3-871,485 4-59,739
Distribution
≤ 9 20 (16%) 13 (15%) 7 (19%) NS *
9-20 10 (8%) 7 (8%) 3 (8%) NS *
20-100 27 (22%) 10 (12%) 17 (46%) p< 0.001 *
100-1,000 15 (12%) 11 (13%) 4 (11%) p< 0.001 *
1,000-10,000 27 (22%) 23 (27%) 4 (11%) p = 0.01 *
>10,000 23 (19%) 21 (25%) 2 (5%)
† P values were obtained by Fisher’s exact test, two-tailed t test or non-
parametric Mann–Whitney U test.
{ p< 0.001 when comparing HCC developing under age 40 in HBV vs. HCV.
* p values obtained when comparing distribution with AFP cut-off at 9, 20,
100, 1,000, or 10,000 in HBV vs. HCV.
NS: not significant.
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HCC patients (p< 0.001, Table 1).
The median age upon initial diagnosis for patients with
either HBV or HCV-associated HCC’s was similar (HBV,
50 years; HCV, 58 years); however, the age distribution in
the two groups differed considerably. Approximately one
fourth (26%) of all HBV-associated HCC’s occurred in
patients aged 40 years or younger, while no cancers
developed in patients under the age of 40 in the HCV
group (p< 0.001, Table 1). In fact, only 2 HCC’s (5%) oc-
curred in the HCV group at 50 years of age or less. This
contrasted with the HBV group, in whom nearly half
(49%) of cancers had already occurred by the age of 50
(Table 1).
As a group, patients who developed HCC associated
with underlying HBV had fewer systemic comorbidities
than those with underlying HCV. A mean of 1.0 under-
lying systemic comorbidity was present in HBV patients
at the time of initial cancer diagnosis, compared with a
mean of 2.9 associated systemic comorbidities in HCV
patients (Table 1, p< 0.001). A coincident history of al-
cohol abuse was also less frequent in the HBV group
(7% in HBV vs. 32% in HCV, p< 0.001), as was the fre-
quency of HIV co-infection (1% in HBV vs. 13% HCV,
p< 0.001).
Co-existence of cirrhosis in the non-neoplastic liver
Patients with underlying HBV were less likely to have
developed cirrhosis at the time of progression to cancer
compared with patients with underlying HCV (p< 0.001,
Table 1). Without exception, all patients who developed
HCC in a setting of chronic HCV had established cir-
rhosis at the time of initial cancer diagnosis. However,40% of patients with underlying HBV developed HCC in
the absence of cirrhosis. When HCC patients with estab-
lished cirrhosis due to either HBV or HCV were com-
pared, the severity of cirrhosis as determined by the
Childs-Pugh classification, was similarly distributed in
both viral hepatitis groups.
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A significant difference in serum alpha-fetoprotein (AFP)-
production was observed in HCC’s associated with under-
lying HBV as opposed to those associated with HCV
(Table 1). The median level of serum AFP in HBV-
associated HCC was greater than HCV-associated HCC
(1000 ng/ml vs. 37 ng/ml, p = 0.002). While the proportion
of patients with normal level of serum AFP (<20 ng/ml)
was similar between HBV- and HCV-associated HCC, the
proportion of HCC producing higher amount of AFP
(>100 ng/ml) was greater in HBV-associated HCC. Sixty
five percent of HBV-associated HCC, in contrast to only
27% of HCV-associated HCC, produced AFP greater than
100 ng/ml (p< 0.001). Similarly, the proportion of HBV-
associated HCC producing AFP greater than 1,000 ng/ml
or 10,000 ng/ml was higher compared with HCV-
associated HCC (52% vs. 16%, and 25% vs. 5%, respect-
ively, Table 1).
Oncologic prognostic variables
The presence upon initial cancer diagnosis of several
well established oncologic variables associated with a
poor cancer specific prognosis was assessed according to
underlying viral hepatitis status. These include tumor
size, tumor number, macrovascular invasion, and the
presence of synchronous distant metastases.
Patients with HBV-associated HCC were significantly
more likely to be diagnosed with larger tumors, than
those with HCV-associated HCC. Seventy eight percent
of HBV-associated tumors exceeded 5 cm in greatest
cross-sectional diameter, as compared with only 28% of
those associated with HCV (p< 0.001, Table 2). Analysis
of all other selected variables failed to demonstrate a sig-
nificant difference according to viral hepatitis status.
Multifocal tumors and macrovascular invasion occurred
with similar frequency in both the HBV and HCVTable 2 Indicators of poor prognosis and their
association with underlying viral hepatitis status
HBV HCV P value
Tumor Size (n = 122)
<5 cm 19 (22%) 23 (61%)
>5 cm 66 (78%) 14 (28%) p< 0.001
Tumor Number (n = 122)
solitary 43 (51%) 17 (46%)
multiple 42 (49%) 20 (54%) NS
Synchronous Metastases (n = 116)
absent 71 (85%) 30 (94%)
present 13 (15%) 2 (6%) NS
Macro-Vascular Invasion (n = 117)
absent 57 (69%) 26 (76%)
present 26 (31%) 8 (24%) NSgroups (HBV-49% vs. HCV-54% and HBV-31% vs. HCV-
24%, respectively). The incidence of synchronous distant
metastases was observed with double the frequency in
HBV patients, when compared to those with HCV
(HBV-15% vs. HCV-6%). However, this trend did not
achieve statistical significance, likely due to statistical
underpowering of the study at the current sample size.
Eligibility for treatment with curative intent
Eligibility for liver transplantation and surgical resection
with expected favorable long-term survival, according to
underlying viral hepatitis status, was determined by ap-
plication of the Milan criteria [12,13]. Patients with
HBV-associated cancers were far less likely to meet these
criteria upon initial HCC diagnosis than were those with
HCV-associated cancers (14% vs. 34%, respectively, p
< 0.05). This more commonly precluded treatment with
expectation for cure in patients with HBV-associated
HCC, when compared to patients with HCV.
Discussion
Viral Hepatitis B and Hepatitis C are the most com-
monly implicated risk factors for HCC, with HBV re-
sponsible for the majority of cases worldwide. The
epidemiologic predominance of HBV-associated HCC
worldwide is largely due to the endemic nature of HBV
infection in East Asian and subsaharan African popula-
tions [14]. Given the broad ethnic and racial diversity of
patients seen at the single New York institution from
which data was collected (Bellevue Hospital Center),
patients included in the current analysis closely resemble
the global demographic for HCC [2,3]. Sixty percent of
all HCC cases were due to underlying HBV, and 25%
were due to HCV. The majority of patients in the HBV
group were of East Asian race (90%), compared to only
5% in the HCV group. This statistic potentially explains
the significant disparity in age at initial cancer diagnosis
among HBV vs. HCV-infected patients. HBV transmis-
sion in East Asian populations predominantly follows
vertical (maternal-fetal) patterns of transmission [15]. In
contrast, HBV in non-Asian populations, and HCV are
more frequently transmitted in horizontal patterns as a
result of exposure to infected body fluids [16-18]. Thus
HCV exposure usually occurs later in life compared to
HBV in the largest worldwide at risk populations. This
finding from our study is consistent with previous stud-
ies in Japan showing younger detection age in HBV
HCC patients compared with HCV HCC patients
[19,20]. Although the mechanistic sequence of events
required for progression from chronic viral hepatitis in-
fection to HCC are poorly understood, a reasonable con-
clusion based on the current data could imply that the
young age associated with HBV-HCC occurs as a direct
result of vertical HBV transmission. Thus screening for
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vertically-transmitted HCC should begin at an early age,
no later than early adulthood.
Another important difference in the progression to
HCC among HBV vs. HCV infected patients is the asso-
ciation to pre-existing cirrhosis at the time of initial can-
cer diagnosis. The occurrence of HCC in the absence of
cirrhosis in a substantial percentage of HBV-HCC
patients (40%), compared to the invariable association to
established cirrhosis in those with HCV-HCC, suggests a
potential cirrhosis-independent pathway to cancer
unique (among viral hepatitis-associated cancers) to
HBV-HCC. Much of the literature suggests a generally
accepted common pathway to hepatocarcinogenesis,
proposed in both HBV and HCV patients, based on: ac-
tive viral replication, chronic hepatocellular necroinflam-
matory activity, hepatic parenchymal fibrosis, cirrhosis,
and eventually cancer [21-23]. Although this model
appears valid for patients with HCV, some with HBV do
not experience such a predictable sequence of events
prior to developing liver cancer [24-26].
Considerations relevant to the care of patients who
are subject to a cirrhosis-independent pathway to HCC
should lead to proposed changes in current widely-
adopted practices of screening for HCC in patients
with chronic HBV [27-29]. Proposed changes in sur-
veillance practices, particularly in those suspected of
perinatal infection, should include a high level of vigi-
lance for cancer even in the absence of cirrhosis. Sev-
eral levels of evidence, in addition to the current data,
reinforce that HBV patients are at risk for HCC even
prior to the development of cirrhosis. Thus HCC
screening should not be withheld until evidence of ac-
tive hepatocellular necroinflammation or cirrhosis are
observed.
Several additional significant clinical-pathologic differ-
ences in HCC were also observed according to under-
lying viral hepatitis status, including AFP production.
This observation is particularly interesting, given that
the utility of serum AFP as a cancer screening tool has
been the subject of considerable recent debate, leading
some experts in the field to not advocate its use as a
tumor marker [30]. In the current study, median AFP
level in HCV-associated HCC was 37 ng/ml, compared
with 1000 ng/ml in HBV-associated HCC, and only 27%
among HCV-associated cancers produced serum AFP
greater than 100 ng/ml, compared with 65% in of HBV-
associated HCC. This result suggests a higher sensitivity
of serum AFP as a tumor marker when used in patients
with HBV, but maybe less so in screening patients with
HCV for cancer.
Oncologic variables with established prognostic signifi-
cance were evaluated according to viral hepatitis status.
Both macrovascular invasion and synchronous metastasesoccurred with greater frequency in the HBV-HCC group,
although these observations did not achieve statistical sig-
nificance. Only tumor size on initial HCC diagnosis, an
important prognostic indicator, was statistically different
among HBV vs. HCV patients [31-33]. This tumor size
discrepancy may be explainable by less rigorous cancer
screening recommendations for patients with chronic
HBV, compared to more uniform and frequent screening
programs for patients with HCV [34,35]. Many of the
accrued HBV-HCC patients would not have met current
American Association for the Study of Liver Diseases
(AASLD) guidelines for HCC screening due to their young
age, absence of cirrhosis or other variables [30]. Thus a
relatively delayed cancer diagnosis may be attributable in
part to under screening of HBV patients for HCC, when
compared to those with chronic HCV.
Often due to initial presentation with large tumors,
patients in the HBV-HCC group were less likely to
meet Milan eligibility criteria for liver transplantation
(single tumor <5 cm in greatest diameter or multiple
tumor each <3 cm in greatest diameter) [12]. Due to
the similar prognostic importance of applying Milan
criteria to surgical resection series, this association to
larger tumors also predicted a lower likelihood of surgi-
cal resection with expected favorable long term survival
[13,36,37]. Overall a staggeringly small fraction of all
patients with HCC associated with either hepatitis virus
met Milan criteria, underscoring the fact that most
patients (80%) cannot be treated with the two most ef-
fective treatments or an expectation for favorable long
term outcome. However, despite this observation in
both viral hepatitis patients, inoperable or poor progno-
sis cancers were significantly more common in patients
with HBV. Whether HBV or HCV viral etiology is an
independent prognostic factor in patients with HCC
following surgical resection or liver transplantation
remains controversial and requires further investigation
[38-42].Conclusions
In summary, patients with HBV-associated HCC were
more likely to present with poor-prognosis cancers,
often at a young age, and in the absence of cirrhosis. In
contrast, patients with HCV-associated HCC often were
diagnosed in a setting of pre-existing cirrhosis, with
multiple comorbidities, but with more favorable oncolo-
gic features. These data suggest a role for more aggres-
sive screening and management of chronic HBV
patients, particularly those subjected to maternal-fetal
viral transmission. The importance of earlier screening
and more aggressive treatment is especially emphasized
by the advanced oncologic nature of HCC associated
with HBV on typical initial diagnosis.
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